The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...

On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $8.91 which represents a decrease of $-0.27 or -2.94% from the prior close of $9.18. The stock opened at $9.25 and touched a low of ...

Drug maker Novavax Inc. (NVAX), while reporting narrower net loss in its third quarter, on Tuesday trimmed its fiscal 2024 forecast ...

On Thursday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.18 which represents a slight increase of $0.22 or 2.46% from the prior close of $8.96. The stock opened at $9.16 and ...